Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Molecular progression defined by longitudinal ctDNA dynamics for prediction of outcomes in immune checkpoint inhibitor–treated solid tumors.

Muhammad Anees, Patrick Wagner, Ashten N. Omstead et al. Jun 01, 2026 pp. 2572-2572 10.1200/jco.2026.44.16_suppl.2572

2572 Background: Reliable early biomarkers of immune checkpoint inhibitor (ICI) resistance remain an unmet need due to del...

The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.

Alexandra Leary, Toon Van Gorp, Frederik Marmé et al. Jun 01, 2026 pp. 5510-5510 10.1200/jco.2026.44.16_suppl.5510

5510 Background: OSE2101 is a neo-epitope vaccine targeting 5 tumor-associated antigens (TP53, MAGE2, MAGE3, CEA and HER2)...

Validation of Immunoscore for prognostic stratification in HPV-associated oropharyngeal cancer: An international multicenter study.

Dac Hung Nguyen, Amine Majdi, Florence Marliot et al. Jun 01, 2026 pp. 6077-6077 10.1200/jco.2026.44.16_suppl.6077

6077 Background: Treatment optimization in HPV-associated oropharyngeal cancer (OPSCC) remains challenging due to the limi...

Epimedin A to prevent glioblastoma growth and invasion.

Erick Zecena, Michael Mildner, Kota Ramana Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14078

e14078 Background: Glioblastomas (U87) are an aggressive brain tumor that arises from glial cells and invades surrounding...

Heart failure–related mortality among U.S. liver and intrahepatic bile duct cancer patients: A 25-year CDC WONDER analysis.

Syeda Saher Fatima, Elangovan Krishnan, Sophia Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16220

e16220 Background: Liver and intrahepatic bile duct cancer (L/IBDC) is a leading cause of cancer mortality worldwide. Como...

Prognosis of mediastinal lymph node metastases in pediatric patients with osteosarcoma and lung metastases.

Lee Ann Santore, Avantika Narasimhan, Peter Schoettler et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22006

e22006 Background: Metastasectomy is recommended for select pediatric patients with osteosarcoma with resectable pulmonary...

Late hematological toxicity after chemotherapy: Exome analysis with long-term follow-up in Mexican population.

Myrna Candelaria, Olga Gutierrez-Hernandez, Jose de la Luz Diaz-Chavez Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24145

e24145 Background: Genomic alterations chemotherapy-induced are associated with cytopenias, myelodysplasia, or acute leuke...

Advancing career-focused training: Program leader perspectives on professional development pathways in hematology/oncology fellowships.

Lauren O'Loughlin, Katherine Ann Scilla, Rushad Patell et al. Jun 01, 2026 pp. 9008-9008 10.1200/jco.2026.44.16_suppl.9008

9008 Background: Hematology/Oncology (H/O) fellows have diverse career opportunities post-graduation. Many fellowship prog...

Clonal hematopoiesis in head and neck carcinomas receiving immunotherapy.

Niki Gavrielatou, Aris Spathis, Kyriaki Mandreka et al. Jun 01, 2026 pp. 6064-6064 10.1200/jco.2026.44.16_suppl.6064

6064 Background: Clonal hematopoiesis (CH) is an age-related accumulation of somatic genetic alterations in hematopoietic...

Smoking signature as used to define a genomically distinct subset of class I BRAF-mutant NSCLC.

Shuai Wang, Roupen Odabashian, Nishant Gandhi et al. Jun 01, 2026 pp. 8538-8538 10.1200/jco.2026.44.16_suppl.8538

8538 Background: Class I BRAF mutant ( BRAF...

Associated antitumor effects of oncoytic vaccinia virus expressing a tethered IL-12/IL-2 fusion cytokine.

Pingpo Ming, Junjie Ye, Lingjuan Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14557

e14557 Background: Cancer immunotherapy has revolutionized cancer treatment, but many solid tumors remain non-inflamed and...

Proton or photon? Comparative survival and toxicity outcomes in lung cancer radiotherapy: A systematic review and meta-analysis.

Roshan Mustafa Pathan, Jugraj Singh, Nabiha Tabassum et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20048

e20048 Background: Radiotherapy (RT) is a cornerstone in non-small cell lung cancer (NSCLC) management. Conventional photo...

Cerebrovascular mortality in patients with head and neck cancer in the United States, 1999-2023: A population-based analysis.

Arfa Ahmad, Muhammad Shaheer Mannan, Abdul basit Khan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18106

e18106 Background: Survival gains in head and neck cancer (HNC) have increased the importance of non-cancer mortality in o...

A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.

Margaret Ottaviano, Domenico Mallardo, Ester Simeone et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps9612

TPS9612 Background: Neoadjuvant immunotherapy, administered upfront of surgery in patients with resectable stage III melan...

Clinicopathologic and imaging predictors of pathologic complete response after neoadjuvant chemoimmunotherapy in resectable NSCLC: A systematic review and meta-analysis.

Claudia Bardoni, Lorenzo Spaggiari, Juliana Guarize et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20068

e20068 Background: Neoadjuvant chemoimmunotherapy (CIT) improves pathologic complete response (pCR) rates in resectable no...

Racial and ethnic disparities in breast cancer care: Barriers associated with treatment delays.

Carmin Munoz, Luz Mata, Christine Shatrowsky et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12706

e12706 Background: Breast cancer is one of the most common cancers among women. Yet, disparities in access to a timely dia...

Prognostic impact of estrogen and progesterone receptor expression disparity in early-stage HR+/HER2- breast cancer.

Yuqin Zhou, Chengwang Wang, Jia Ming et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12534

e12534 Background: In hormone receptor-positive, HER2-negative early-stage breast cancer (HR+/HER2- EBC), the biological c...

Impact of remote symptom monitoring program on payor-specific healthcare costs.

Gabrielle Betty Rocque, Jeffrey Franks, Sandra C. Olisakwe et al. Jun 01, 2026 pp. 1632-1632 10.1200/jco.2026.44.16_suppl.1632

1632 Background: Remote symptom monitoring (RSM) programs are currently being implemented across oncology practices nation...

Real-world treatment patterns and survival outcomes in splenic marginal zone lymphoma: A SEER analysis (2000-2022).

Tushar Abhinav, Nikita Garg, Akshat Saxena et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19096

e19096 Background: Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell non-Hodgkin lymphoma with heterogeneou...

Comparative effectiveness of pembrolizumab and nivolumab as first-line treatment for advanced/unresectable or metastatic melanoma: A propensity-score adjusted analysis from a US national health system.

Josiah Nieto, Garth Strohbehn, Daniel A. Goldstein et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21513

e21513 Background: Therapies targeting programmed cell death protein 1 (PD1) are mainstays of modern cancer therapy. Pembr...

Longitudinal changes in pulmonary function following multiple courses of thoracic radiotherapy.

Rohith Kesaraju, Shruti Jolly, Charles Matrosic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20103

e20103 Background: Pulmonary function decline following thoracic radiotherapy (RT), particularly DLCO, is well documented...

Improving resident education in ambulatory oncology: A novel flipped-classroom curriculum for internal medicine residents.

Mary Metkus, Kristen A. Marrone, Paul O'Rourke Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21009

e21009 Background: There is a paucity of oncology curricula for internal medicine (IM) residents, particularly related to...

Assessing the performance of ChatGPT in addressing ethical dilemmas in oncology.

Christabelle Junaidi, Anita Ho, Brian Schulte Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23292

e23292 Background: Large language models such as ChatGPT have been shown to demonstrate accuracy in diagnostic reasoning a...

Clinical outcomes of gabapentinoids for oncologic pruritus: A retrospective cohort study.

Alim Osman, Ian Nykaza, Stephen W. Dusza et al. Jun 01, 2026 pp. 12066-12066 10.1200/jco.2026.44.16_suppl.12066

12066 Background: Pruritus is a debilitating symptom in oncologic patients, sometimes leading to interruption of cancer th...

Escalating site burden and cost: What’s driving the surge in oncology investigator grants over the past decade.

Ashley Herrick, Meera Belur, Elaina Haeuber Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23149

e23149 Background: Publicly accessible data and industry analyses strongly confirm that site costs, including investigator...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page